Skip to main content
OpenTrials
Completed

NCT Number: NCT03838094

Evaluation of MTA Versus Biodentine as Pulpotomy Agents in Immature First Permanent Molars

Aim of the study: To compare the clinical and radiographic outcomes of mineral trioxide aggregate (MTA) and Biodentine as vital pulp therapy materials (pulpotomy) of cariously exposed vital immature mandibular first permanent molars.

Materials and Methods: sixty immature first mandibular permanent molars cariously exposed with symptomatic /asymptomatic pulpitis were included in the study according to inclusion criteria and were equally divided in two groups. Following split-mouth design molars were randomly assigned to either a control group (MTA 30 molars) or a test group (Biodentine 30 molars). After conducting pulpotomy and covering pulp stumps with the MTA and Biodentine, treated molars received permanent restorations. Blinded clinical and radiographic evaluations were performed at different time intervals (base line immediate postoperative, 6, 12 and 18 months) according to clinical and radiographic criteria of success. Data were recorded and analysed.

Completed

Looking for future studies?

Notify Me

Key information

Age range

7 year–8 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

About this study

Diagnosis:

  • Full history data will be collected, including personal, medical and previous dental data
  • Clinical examination using mirror and probe to assess the inclusion criteria.
  • Radiographic examination using preoperative digital periapical radiograph to assess the inclusion criteria.
  • Preoperative photograph will be taken.

Operative procedure:

Experimental group:

  • Injection of local anesthesia and rubber dam isolation.
  • caries and roof of the pulp chamber will be removed by a fissure diamond bur (Diatech, Heerbrug, Switzerland) and high-speed handpiece with coolant.
  • The pulps will be amputated to the orifice level using a long-shank diamond round bur.
  • Haemostasis will be achieved by gentle placement of a saline-moistened cotton pellet over amputated pulps for 5-10 min.
  • Calcium silicate-based BiodentineTM (Septodont Ltd., Saint Maur des Fausse´s, France) will be mixed according to the manufacturer's instructions, radicular pulp will be covered by the material using a wet cotton pellet.
  • A self-cure glass ionomer (GC; GC Corporation, Tokyo, Japan) will be placed over the pulpotomy agent as a final restoration.
  • Immediate post-operative radiograph and photograph will be taken.

Control group:

The same procedures will be carried out as the experimental group, but the pulp stumps will be covered with fast-setting mineral trioxide aggregate (MTA) ENDOCEM MTA (Maruchi, Wonju, Korea) and will be prepared according to the manufacturer's instructions. A 3-mm-thick layer of MTA will be placed over the amputated pulps and will be gently adapted to the dentinal walls using a wet cotton pellet. A self-cure glass ionomer (GC; GC Corporation, Tokyo, Japan) will be placed over the pulpotomy agent as a final restoration.

Postoperative care:

Instructions to avoid lip and cheek biting in addition to oral hygiene measures.

Follow up:

Assess the outcomes clinically and radiographically at (baseline, 6, 12 and 18 months).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Bilaterally Symptomatic ⁄ asymptomatic vital immature mandibular first permanent molars (with clinical carious exposure of the pulp and presence of bleeding upon exposure)
  • Patients with an age range from 7-8 years.
  • Absence of sinus tract, soft tissue swelling.

Exclusion criteria

  • • Molars were excluded if non-restorable.
  • excessive mobility (more than 1 mm horizontally).
  • Radiographic evidence of peri- and ⁄or inter-radicular lesions, internal⁄ external root resorption, pulp⁄ canal calcifications.

Treatment and study plan

Biodentine

Biological

it is a dentin substitute, a new biologically active material facilitates its penetration through opened dentinal tubules to crystallize interlocking with dentin and provide mechanical properties.

Other names: Calcium silicate-based biomaterial

MTA

Biological

MTA is a powder that consists of fine hydrophilic particles that set in the presence of moisture. MTA consists of tricalcium silicate, tricalcium aluminate, tricalcium oxide and silicate oxide. MTA was considered a remarkable biocompatible material with various clinical applications that include surgical and non-surgical applications such as pulp capping

Other names: mineral trioxide aggregate

Primary outcomes

  1. pain, sensitivity to percussion⁄ palpation

    Time frame: 18 months

    by asking the patient( binary measure)Yes or No, where Yes indicates presence of pain that shows clinical failure

  2. Swelling or sinus tract

    Time frame: 18 months

    by visual examination( Binary measure) (Yes or No) where No indicates success of the treatment

  3. tooth mobility

    Time frame: 18 months

    by back of the mirror( Binary measure) (Yes or No) where No mobility indicates success of the treatment

Secondary outcomes

  1. root formation/development stage

    Time frame: 18 months

    by radiographic parallel technique to measure the maturity scores used during the radiographic assessment of root development are F, G and H (where F is the worse and H is the best stage)

  2. Crown: Root ratio

    Time frame: 18 months

    by radiographic parallel technique ( the ratio 2:1 or more than 2:1) the ratio more than 2:1 is the best

  3. Apical closure

    Time frame: 18 months

    by radiographic parallel technique( the apex is blunder apex ,partially open, or constricted) blunder apex is the worse and constricted apex is the best.

  4. presence of radiolucency

    Time frame: 18 month

    by radiographic parallel technique( binary measure)( yes or No) if radiolucency is detected this indicates failure of the treatment

Sponsors and collaborators

Lead sponsor

Gihan M Abuelniel ,PhD

Other

Collaborators

  • Cairo University

Registry information

Official study title

Clinical and Radiographic Evaluation of MTA Versus Biodentine as Pulpotomy Agents in Immature First Permanent Molars: A Randomized Clinical Trial

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Feb 12, 2019
Registry last updated
Feb 12, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.